Essential Thrombocythemia clinical trials

Explore recruiting essential thrombocythemia clinical trials.

Recruiting essential thrombocythemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Essential Thrombocythemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants

Denmark, Italy, Sweden, France, Germany, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ruxolitinib versus Best Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The Ruxo-BEAT Trial

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Open-label, Active-Comparator-Controlled Clinical Study to Evaluate the Safety and Efficacy of Bomedemstat (MK-3543/IMG-7289) versus Best Available Therapy (BAT) in Participants With Essential Thrombocythemia who have an Inadequate Response to or are Intolerant of Hydroxyurea

Spain, France, Germany, Netherlands, Sweden, Poland +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia

Spain, Germany, Italy, France, Denmark

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Essential Thrombocythemia trials by city

Essential Thrombocythemia in Toronto Essential Thrombocythemia in Vancouver Essential Thrombocythemia in Montreal Essential Thrombocythemia in Calgary Essential Thrombocythemia in Edmonton Essential Thrombocythemia in Ottawa Essential Thrombocythemia in Winnipeg Essential Thrombocythemia in Quebec City Essential Thrombocythemia in Hamilton Essential Thrombocythemia in Kitchener Essential Thrombocythemia in London Essential Thrombocythemia in Halifax Essential Thrombocythemia in New York Essential Thrombocythemia in Los Angeles Essential Thrombocythemia in Chicago Essential Thrombocythemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease